What is the difference between Jisandai and Bingtonsha?

Epclusa and Pangenet are actually different names for the same drug, and both are hepatitis C treatments developed by Gilead Sciences. Their core ingredients include two antiviral drugs: Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). The combined use of these two drugs can effectively treat hepatitis C virus (HCV) infection and has broad-spectrum antiviral effects. Therefore, there is no essential difference in the treatment mechanism between Jisandai and Bingtongsha, and they are both first-line treatment options for hepatitis C.

The pharmaceutical ingredients of GISANDA and protonsa are the same, including sofosbuvir and velpatasvir. Sofosbuvir is a nucleoside reverse transcriptase inhibitor that can inhibit the RNA polymerase of hepatitis C virus, thereby preventing the replication of the virus. Velpatasvir is an NS5A inhibitor that interferes with the replication and assembly of the virus by inhibiting the NS5A protein of HCV. The two work together through these two mechanisms to effectively inhibit the proliferation of hepatitis C virus and achieve a curative effect.

Gisanda and Bingtonsa are used in clinical applications to treat all genotypes of hepatitis C (1-6types) and are suitable for different patient groups, including patients without cirrhosis and some patients with cirrhosis. Whether it is treating acute hepatitis C or chronic hepatitis C, Jisandai and Bingtongsha can achieve significant results. The treatment plan for both is usually 12 weeks and is effective for most patients, with a cure rate of over 95%.

The side effects of Jisandai and Bingtongsha are usually mild, and the most common ones include headache, fatigue, nausea, insomnia, etc. Most of these side effects appear in the first few weeks of treatment and gradually reduce as the treatment progresses. Although the side effects of the two are similar, individual patients may have different tolerances, so when used, individualized adjustments are still needed based on the patient's specific conditions.

Reference: https://www.epclusa.com/